Short Interest in Kamada Ltd. (NASDAQ:KMDA) Grows By 33.3%

Kamada Ltd. (NASDAQ:KMDA) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 23,200 shares, a growth of 33.3% from the December 31st total of 17,400 shares. Based on an average daily volume of 63,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the shares of the company are short sold.

Kamada Trading Up 0.3 %

NASDAQ KMDA traded up $0.02 on Friday, hitting $6.73. 45,552 shares of the company traded hands, compared to its average volume of 154,608. The business’s 50 day moving average price is $6.42 and its 200-day moving average price is $5.86. Kamada has a 52-week low of $4.74 and a 52-week high of $8.00. The company has a market capitalization of $386.84 million, a price-to-earnings ratio of 24.04, a P/E/G ratio of 0.86 and a beta of 0.98.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Kamada in a research report on Friday, January 10th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kamada stock. Plato Investment Management Ltd acquired a new stake in shares of Kamada Ltd. (NASDAQ:KMDA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.